Asia Pacific Breast Lesion Localization Methods Market Size, Share & Trends Analysis Report By Type (Wire localization, Radioisotope localization, Magnetic Localization, Others), By Usage (Tumor Identification, Sentinel Lymph Node Identification) and By Country(China, Korea, Japan, India, Australia, Taiwan, Southeast Asia, Rest of Asia-Pacific) Forecasts, 2024-2032

Market Overview

The Asia Pacific breast lesion localization methods market size has witnessed significant growth in the past and is expected to grow at a CAGR of 18.2% during the forecast period (2022–2031). According to the World Health Organization (WHO), the breast cancer diagnosis rate in the Asia Pacific region is relatively lower at 29.1 per 100,000 women compared to the global average of 43 per 100,000.

The acceptance and utilization of breast lesion localization methods such as MRI, ultrasound, and mammography depend on the healthcare infrastructure of the respective systems. The Asia Pacific region is home to over 60% of the global population, with India and China accounting for more than 35%. However, the prevalence of breast cancer varies among different countries. China, in particular, experiences a significant number of breast cancer cases annually, making it the leading cause of death among women. Approximately 36 out of 100,000 women in China are diagnosed with breast cancer every year.

Market Dynamics

Asia pacific breast lesion localization methods and market drivers

Growing prevalence of breast cancer

The evolving market trends and increased presence of IT companies have caused a shift in people's focus away from their physical well-being. This is supported by a sedentary lifestyle, particularly among working women who spend less time cooking and opt for calorie-rich packaged and fast foods. These changes in dietary habits have contributed to the growing problem of obesity, which is a significant factor in the increasing incidence of breast cancer. Additionally, higher alcohol consumption is exacerbating the prevalence of breast cancer.

Escalating health insurance penetration

The expensive nature of cancer treatment presents a significant challenge to the market's growth. However, there has been a notable increase in individuals' adoption of healthcare insurance plans. These countries offer some of the most affordable healthcare insurance options worldwide. This has led to improved access to health insurance coverage, alleviating concerns about the cost of cancer treatment. As a result, more individuals are likely to seek the expertise of oncologists, knowing that the financial burden will be somewhat relieved.

Asia pacific breast lesion localization methods market restraint

Scarcity of skilled oncology specialists

Enough oncologists are crucial to ensure the optimal diagnosis, treatment, and care of individuals with cancer. However, there is a significant shortage of skilled oncologists capable of delivering comprehensive and high-quality care. Moreover, access to advanced localization technology is limited to developed countries due to inadequate healthcare infrastructure in other regions. Additionally, many hospitals that offer oncology services lack the necessary equipment and technologies for precise diagnosis and treatment of breast cancer.

Asia pacific breast lesion localization methods market opportunities

Promising opportunities in developing markets

Rapid urbanization in these countries has led to a significant migration of people towards urban areas. This has created a need for government and private entities to expand their healthcare infrastructure to accommodate the growing population. Our research findings indicate that government hospitals in these regions lack technology and resources, which has prompted private hospitals to make substantial investments in acquiring advanced equipment to attract more patients and take advantage of the gap in public healthcare services. Furthermore, these governments offer various incentives to encourage the establishment of new hospitals, such as providing affordable or free land, offering incentives based on the number of patients treated, providing subsidies for treatment costs, and facilitating easy access to loans to procure necessary machinery. As a result, many private players are constructing new hospitals and expanding their networks to establish their brands and strengthen their position in the market.

Regional Analysis

The breast lesion localization methods market is segmented by country: China, India, Japan, Southeast Asia, Korea, Australia, and the Rest of Asia Pacific. China dominated the market with a CAGR of 18.6% during the forecast period.

The Asia Pacific region is a key market for breast lesion localization methods. The demand for effective breast cancer diagnosis and treatment is rising with a rapidly growing population and increasing healthcare awareness. Countries like China, Japan, and India are witnessing significant market growth, driven by advancements in healthcare infrastructure and the adoption of advanced localization technologies.

Breast cancer affects a significant number of Chinese women each year. It is the primary cause of death among women. More than 36 per 100,000 women are diagnosed with breast cancer annually in the United States. For example, urban women are more likely to contract the disease than their rural counterparts. Increasing numbers of people are migrating to megacities due to the country's accelerated urbanization. This has increased the prevalence even further.

In minor cities (population less than 500,000), breast cancer incidence is 30 per 100,000. For cities with a population between 500,000 and 1,000,000, the rate is 40 per 100,000. And in major cities (population greater than one million), the incidence rate is sixty per one hundred thousand women. This is primarily attributable to changes in stress levels, lifestyle changes, and aging.

Japan and South Korea have the greatest breast cancer incidence rates in eastern Asia (51.5 and 52.1 per 100,000, respectively), while Singapore has the highest rate in southeast Asia (65.7 per 100,000). The observed increase in breast cancer incidence rates varies among Asian countries, with Japan experiencing an annual increase of 6%.

Segmental Analysis

The Asia Pacific breast lesion localization methods market is segmented into type and usage.

By type it is further segmented into wire localization, radioisotope localization, magnetic localization, and others.

Wire localization dominated the market and is expected to register a CAGR of 18.5% over the forecast period. Wire localization is used to designate the precise location of the lesion, which assists the surgeon in detecting and removing breast lesions if an X-ray reveals multiple lesions. The technique is favored for removing lesions or tumors that are difficult to locate and cannot be felt. In addition, it can be used to remove the smallest possible area, which would be difficult for a surgeon to do without causing obvious harm to the surrounding tissue. The procedure is painless, but some women may experience pressure or vertigo.

It is further segmented based on usage into tumor identification and sentinel lymph node identification.

Tumor identification dominated the market and is expected to register a CAGR of 17.7% over the forecast period. A physical examination, or breast imaging, which primarily consists of mammography and a biopsy, is performed to identify tumors. It is commonly performed on women with breast cancer. Mammography utilizes X-rays to image the breast region containing a tumor. In addition, various imaging technologies, such as MRI and ultrasound, are also utilized. Ultrasound is primarily recommended for women under the age of 30.

Recent Developments

• January 2021: Hologic, Inc., an innovative medical technology company focused on improving women’s health, announced and completed the acquisition of SOMATEX Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, for approximately USD 64 million. The company was previously owned by E-Med Solutions GmbH, Berlin, a group of investors led by German private equity company Westlake Partners.